Huang-long Zhi-xiao Granule Improves the Control Rate of Chronic Persistent of Asthma

Inclusion Criteria: Patients who meet the diagnostic criteria for chronic persistent bronchial asthma It meets the TCM differentiation standards for wheezing and hot wheezing Asthma Control Test (ACT) questionnaire score<20 score The severity of disease is graded from mild to moderately persistent Patients who have not been treated with anti-asthmatic drugs for 2 weeks prior to dosing or who have been treated with ICS or ICS+LABA for 4 weeks or more prior to dosing and who have the same type and dose of the drug Age form 18-80 years old Have not participated in other clinical studies within 1 month prior to enrollment Voluntarily participate in the study and sign an informed consent form Exclusion Criteria: Patients with special types of refractory asthma, critical asthma, occupational asthma, seasonal asthma, atypical asthma or tuberculosis, pulmonary interstitial fibrosis, thoracic malformation, chronic obstructive pulmonary disease, bronchiectasis, cystic pulmonary fibrosis, allergic bronchopulmonary aspergillosis, allergic granulomatous vasculitis, infectious, restrictive lung disease and other airflow obstructive pulmonary diseases Patients with severe cardiovascular and cerebrovascular diseases (malignant arrhythmia, unstable angina, acute myocardial infarction, cardiac function grade 3 and above, stroke, cerebral hemorrhage, etc.) Glutamate aminotransferase (ALT), aspartate aminotransferase (AST) > 1.5 times the upper limit of normal value， blood creatinine (Cr) > upper limit of normal value Those who are allergic and allergic to the components of drugs in known test drugs Patients with bronchiectasis, tuberculosis, pulmonary embolism, or other serious respiratory conditions Combined with severe cognitive and psychiatric abnormalities Participants who are pregnant, lactating, and planning to become pregnant Those who are participating in other clinical trials within 1 month prior to enrollment